CD8A and COVID-19: We agreed with the perspective of Vardhana and Wolchok (1) who hypothesized that CD8+ effector T cells might be redistributed and be consumed during the battle for SARS-CoV-2 in human bodies, especially in the severe cases of COVID-19.